KGaA (MRK:GR) (OTC: MKGAF) stock from Overweight to Equalweight and reduced its price target from EUR190.00 to EUR160.00. The downgrade reflects a shift in the investment firm's perspective on the ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...

Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential ...

(Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by ...

Co., Inc. (NYSE:MRK), recently purchased 2,832.861 shares of the company's common stock. The acquisition, valued at approximately $249,999, was completed at a price of $88.25 per share. Following this ...

Klaus joins Epitopea after serving as Chief Development Officer (CDO) at Nykode Therapeutics, where he oversaw clinical development, regulatory affairs, and project management across oncology, ...

Whether improving the quality of life or the quality of our environment, life and health science students really do make a difference. Well-established links with government agencies, public bodies, ...

A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top ...

In a report released today, Falko Friedrichs from Deutsche Bank maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price ...

The College of Biomedical and Life Sciences is a vibrant academic community, which undertakes innovative research and provides state-of-the-art learning facilities. Researchers from Cardiff University ...

Our teaching excellence feeds into a fantastic array of undergraduate degrees in a variety of subjects, while our ground-breaking research has led to: new treatments for ovarian cancer, the discovery ...